Table 2. Overview of recent and ongoing main trials of MMAE for CSDH.
| Trial name | Country | Size | Completion | Population | Intervention | Embolic agent | Primary outcome | Follow-up |
|---|---|---|---|---|---|---|---|---|
| MMAE + surgery vs. surgery | ||||||||
| METRICS40) | China | 516 | Dec-24 | At least 1 risk factor for recurrence | 1. MMAE + surgery vs. surgery 2. MMAE vs. atorvastatin |
Not stated | Repeat surgery or radiological | 6 months |
| MEMBRANE (USA)42) | USA | 376 | Mar-25 | mRS score ≤3 | 1. MMAE + surgery vs. surgery 2. MMAE vs. conservative |
TRUFILL n-BCA | Repeat surgery or radiological | 6 months |
| OTEMACS37) | France | 440 | May-25 | Symptoms and mRS score ≤3 | 1. MMAE + surgery vs. surgery 2. MMAE vs. conservative |
Onyx | Repeat surgery or radiological | 3 months |
| LEADH43) | France | 550 | Sep-26 | CSDH >10 mm | 1. MMAE + surgery vs. surgery 2. MMAE vs. conservative |
Cyanoacrylates | Symptomatic recurrence or repeat surgery or radiological | 2, 6 months |
| STORMM41) | Switzerland | 180 | Jan-27 | Symptoms or failed conservative | 1. MMAE + surgery vs. surgery 2. MMAE vs. conservative |
Not stated | Symptomatic recurrence or repeat surgery or radiological | 6 months |
| ChiCTR200003935947) | China | 480 | Mar-23 | Symptoms | MMAE + surgery vs. surgery | Not stated | Rate of recurrence | Not stated |
| ENCLOSURE48) | Spain | 280 | Dec-23 | CSDH >10 mm or symptoms | MMAE + surgery vs. surgery | Onyx, Phil, Squid, or Libro | Symptomatic recurrence or radiological | 6 months |
| ELIMINATE44) | Netherlands | 170 | Oct-25 | Age ≥50 years, symptoms | MMAE + surgery vs. surgery | PVA particles | Repeat surgery | 8, 16, 24 weeks |
| MEMBRANE (Germany)49) | Germany | 154 | Oct-25 | Candidate for surgery | MMAE + surgery vs. surgery | PVA particles (mainly) | Repeat surgery or radiological | 3 months |
| EMPROTECT38) | France | 342 | Oct-23 | Recurrence or high risk factor of recurrence | MMAE + surgery vs. conventional treatment | EmboSphere | Repeat surgery or radiological | 6 months |
| EMMA-Can50) | Canada | 200 | Mar-26 | Symptoms and mRS score ≤2 | MMAE + conventional treatment vs. conventional treatment | Particulate polymer or liquid embolic agents | Radiological | 3 months |
| COMPLEMENT39) | Japan | 600 | Mar-29 | Pre-mRS score ≤3, CSDH ≥10 mm, at least 1 risk factor for recurrence | MMAE + conventional treatment vs. conventional treatment | Not stated | Repeat surgery or radiological | 6 months |
| MMAE vs. surgery or conservative | ||||||||
| Embotrial-136) | Italy | 300 | Mar-26 | Markwalder grade ≤1 | MMAE vs. conservative management | PVA particles or liquid embolic agents | Requires surgery or hematoma resolution | 6 months |
| SWEMMA34) | Sweden | 288 | Mar-27 | Markwalder grade <2, GCS >13 | MMAE vs. surgery | Onyx, Squid, or Phil | Repeat surgery | 3 months |
| CHESS33) | USA | 520 | Feb-29 | Age ≥40 years, CSDH >10 mm | MMAE vs. surgery | EmboSphere or Contour | Repeat surgery or death | 6–7 months |
| PREMMA35) | Puerto Rico | 658 | Jul-32 | Markwalder grade ≤2, GCS ≥14 | MMAE vs. surgery | PVA particles | Repeat surgery | 3, 6, 12 months |
Contour, Boston Scientific, Marlborough, MA, USA; CSDH, chronic subdural hematoma; Embosphere, Merit Medical, South Jordan, UT, USA; GCS, Glasgow Coma Scale; Libro, INVAMED, Ankara, Turkey; MMAE, middle meningeal artery embolization; mRS, modified Rankin Scale; n-BCA, N-butyl-2-cyanoacrylate; Onyx, Medtronic, Irvine, CA, USA; PHIL, Terumo Neuro, Aliso Viejo, CA, USA; PVA, polyvinyl acrylate; Squid, Balt, Montmorency, France; TRUFILL, Johnson & Johnson, Irvine, CA, USA